The University of Tokyo · Graduate School of Frontier Sciences · 准教授

Research keywordsCDC7 inhibition・homologous recombination repair・replication stress・cGAS-STING pathway・EGFR tyrosine kinase inhibitor resistance・epithelial-mesenchymal transition・CD70-targeted therapy・SARS-CoV-2 viral fitness・single-cell sequencing・PI3K-Akt-mTOR signaling

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
• Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response.
• Single-cell sequencing techniques from individual to multiomics analyses.
• Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.

• 肺腺がんにおけるEGFR-TKI耐性機構の一細胞解析による解明
• 新規CDC7キナーゼ阻害剤TAK-931の併用療法開発に向けた橋渡し研究
• がん染色体不安定性（CIN）パラドックスの解明とCIN脆弱性を狙った新規治療法の開発
• BRCA2非翻訳領域上に存在する新規生殖細胞突然変異のメカニズム解析

• Official profile